KLK3 and prostate cancer: Recently, several phase I/II clinical trials employing DNA-based vaccines targeting different TAAs (i.e., PSA, PAP, gp100, CEA, hsp65) have been conducted in patients with prostate cancer, melanoma, colorectal cancer, and head and neck carcinomas [53-57].